Plumbagin Inhibits Cadmium-Induced Interleukin-6/STAT3 Signaling in the Triple-Negative Breast Cancer Cell Line

Document Type : Research Articles

Authors

1 Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand.

2 Division of Pharmacology and Biopharmaceutical Sciences, Faculty of Pharmaceutical Sciences, Burapha University, Chonburi 20131, Thailand.

Abstract

Introduction: Plumbagin has been found to reduce proinflammatory cytokine expression in activated macrophages and carrageenan-induced paw edema. Cadmium triggers the release of interleukin-6 (IL-6), a key mediator of inflammation and carcinogenesis in many cell types. The effects of plumbagin on cadmium-induced inflammation in triple-negative breast cancer cells are unknown. Method: We investigated the effects of plumbagin on cadmium-induced IL-6 expression and signal transducer and activator of transcription 3 (STAT3) activation in MDA-MB-231, a triple-negative breast cancer cell line, using real-time PCR, ELISA, and Western blotting. Result: Non-cytotoxic concentrations of cadmium chloride at 1 and 10 μM upregulated the IL-6 mRNA expression after 3 h of exposure and increased the IL-6 release after 24 h. Plumbagin at 4 μM or more was toxic to cells after 24 h. Plumbagin at 1 μM co-treated with cadmium reduced the expression and secretion of IL-6. At 24-h post-exposure, plumbagin decreased the levels of phosphorylated STAT3 induced by cadmium. Conclusion: Plumbagin inhibits cadmium-induced IL-6/STAT3 signaling in a triple-negative breast cancer cell and further in vivo studies are required to elucidate the potential use of plumbagin on cancer progression.

Keywords

Main Subjects

Asian Pacific Journal of Cancer Prevention
Volume 26, Issue 2
February 2025
Pages 465-470

Files

History

  • Receive Date: 08 May 2024
  • Revise Date: 26 September 2024
  • Accept Date: 13 February 2025

Share

How to cite

Statistics